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Introduction
Hemophilia A is an X-linked bleeding disorder caused by mutations in the F8 gene, leading to a deficiency of clotting factor VIII, and occurs in one in every 5000 men. Patients are classified on the basis of residual FVIII concentration (FVIII:C). In this study, we focused on nonsevere hemophilia A patients (moderate and mild disease severity with FVIII:C values of, respectively, 1-5 IU dL Previous studies have shown that non-severe hemophilia A patients have an increased risk of dying from bleeding complications when they develop inhibitors [1, 2] . However, other risk factors predisposing patients to die from bleeding complications may be present. It is important to analyze risk factors for fatal bleeding, as this may provide insights into areas of care that require improvement. Previous studies were mainly focused on fatal bleeding in severely affected patients or addressed the complete hemophilic population, including hemophilia B patients [3] [4] [5] [6] [7] [8] [9] [10] [11] . To our knowledge, there is no study addressing fatal bleeding specifically in non-severe hemophilia A patients.
Intracranial bleeding is the major cause of fatal bleeding [1, [12] [13] [14] . Established risk factors for spontaneous intracranial bleeding in the general population include coagulation disorders such as hemophilia, but also the use of oral anticoagulants or antiplatelet agents, hypertension, smoking, and alcohol consumption [15, 16] . Furthermore, the use of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to a higher bleeding risk, owing to inhibition of platelet aggregation in individuals with a hemostatic disease [17] . As hemophilia A patients more frequently experience joint pain, they may use NSAIDs. Reported risk factors for intracranial bleeding in hemophilic patients are disease severity, inhibitor development, infection with Human Immunodeficiency Virus (HIV), Caucasian ethnicity, prior intracranial bleeding, head trauma, and older age [13, 18] .
We aimed to describe the mortality rates for intracranial bleeding, and to analyze risk factors and comorbidities associated with fatal intracranial bleeding in non-severe hemophilia A patients.
Patients and methods

Study population
The INSIGHT study is an international cohort study of all non-severe hemophilia A patients who were treated with FVIII concentrates during the observation period between 1980 and 2010 in 34 participating centers across Europe and Australia [19] . Clinical data and vital status were collected from 2709 patients [19] . Participating centers (listed in the Appendix) were located in 10 European countries and Australia. The institutional review boards of all participating centers approved the study. As this project involves retrospective data collection, all review boards indicated that informed consent was not required. This study was conducted in accordance with the Declaration of Helsinki.
Data collection
We collected demographic and clinical data from available medical records by using a standardized electronic case report form, as previously described [1] . The following baseline characteristics were collected: date of birth, date of death, ethnicity, baseline FVIII:C (one-stage clotting assay), von Willebrand factor (VWF) antigen level, VWF activity, and inhibitor status.
Definitions and cause of death
For deceased patients, we used the 10th revision of the International Classification of Diseases, Injuries, and Causes of Death of the World Health Organization (ICD10) to classify the primary and secondary cause of death [20] . Furthermore, we collected additional information on mortality related to comorbidities, viral infections, bleeding, cardiovascular disease, and inhibitors.
The Cumulative Illness Rating Scale (CIRS) was used as a standardized instrument to determine comorbidity [21] . For causes of death related to bleeding, we collected information about the location and cause of bleeding.
Inhibitor status was determined on the basis of results of all available inhibitor tests. A clinically relevant inhibitor was defined as the presence of at least two positive titers of ≥ 1.0 Bethesda Inhibitor Assay Units [1] .
Statistical analyses
Summary statistics include frequencies and percentages for categorical variables, and median and interquartile range (IQR) for continuous variables. One-way ANOVA and the chi-squared test were used to compare means between groups.
We calculated the standardized mortality rate (SMR) to compare death following intracranial bleeding in our study population with that in a general population. The SMR is the observed number of deaths following intracranial bleeding in our cohort divided by the expected number of deaths following intracranial bleeding. The expected number of deaths is calculated by multiplying the death rate from intracranial bleeding in the general population by person-years in our cohort. Mortality data on intracranial bleeding in the general population were available for the Dutch male population from 1 January 1996 (start of the ICD10 classification) until 1 January 2011, retrieved from the Statistics Netherlands website [22] . The death rate was calculated for 10-year age groups by dividing the number of deaths by personyears. Person-years per age group for the general population were calculated from the number of males alive per calendar year for each age [23] .
Person-years in the INSIGHT cohort were calculated for each patient as the time between the start of the observation period of the general population (1 January 1996 or date of birth for patients who were born later) and date of death or end of follow-up (1 January 2011, or date lost to follow-up). Person-years and deaths were stratified according to age (10-year groups). Table 1 shows the baseline characteristics of the INSIGHT cohort. In the total study cohort of 2709 mild (n = 1990, 73%) and moderate (n = 719, 27%) hemophilia A patients, the median year of birth was 1970 (IQR 1953 (IQR -1988 . The median age at the end of followup or death was 38 years (IQR 20-56). The population was mostly Caucasian (95%). The median baseline FVIII: C was 10 IU dL À1 (IQR 5-18). The median cumulative number of days of exposure to FVIII concentrates was 13.5 (IQR 6-33). In the total INSIGHT cohort, patients were observed for 64 208 patient-years, and the median follow-up was 29 years (IQR 18-30) per patient . In total, 148 patients (mild, n = 121, 4%; moderate, n = 27, 1%) died during the observation period. The median age at the time of death was 63 years (IQR 44-75).
Results
Patient characteristics
Mortality rates
In 62 of the 148 patients (42%) who died, the cause of death was related to hemophilia A. In this group of 62 patients, 28 (19%) patients died from complications related to infection with hepatitis B/C virus (12%) or HIV (7%). In 34 patients (23%), death was caused by bleeding. Seven of 34 patients died from inhibitor-related bleeding ( Table 2 ). Fatal intracranial bleeding occurred in 17 patients (12%; spontaneous, n = 13; and traumatic, n = 4; Figure 1 ). The mortality rates for fatal intracranial bleeding in our cohort are shown in Table 3 . In our cohort, three patients aged < 30 years died from intracranial bleeding. Fatal intracranial bleeding at all ages occurred 3.5-fold more frequently in non-severe hemophilia A patients than in the general population between 1996 and 2010 (95% confidence interval [CI] 2.0-5.8; Table 4 ).
Risk factors and comorbidities
The characteristics of all deceased patients, classified by cause of death (fatal bleeding or other), are shown in Table 2 . The age of patients with fatal intracranial bleeding showed a tendency to be lower than that of patients with other causes of death (median 59 years versus 65 years, P = 0.057; Table 2 ). Patients with fatal traumatic intracranial bleeding died in an earlier decade than patients with fatal spontaneous intracranial bleeding (median year of death, respectively, 1989 and 2002; P = 0.015). The rate of death related to an inhibitor was significantly higher in patients dying from other bleeds than in patients with fatal intracranial bleeding (P = 0.002; Table 2 ). The prevalence of hypertension was similar in the group of patients dying from (intracranial) bleeding as in patients dying from other causes of death (2/17 versus 4/17 versus 34/114; P = 0.334; Table 2 ). The comorbidities of the patients dying from intracranial bleeding showed no clear pattern that could be informative for distinguishing patients at risk for intracranial bleeding (Table S1 ).
Discussion
This is the first international cohort study to report specific mortality rates for intracranial bleeding in non-severe hemophilia A patients. Intracranial bleeding was the cause of death in 12% of the deceased patients in our cohort. Non-severe hemophilia A patients showed a 3.5-fold higher mortality rate for intracranial bleeding than the general population.
Mortality rates
Previous studies have described mortality rates for intracranial bleeding ranging from 4% to 34%, depending on the population and time period. L€ ovdahl et al. reported that, in the total Swedish hemophilic population between 1968 and 2009, 4% of the deceased patients died from intracerebral bleeds [4] . Plug et al. reported causes of death in the total Dutch hemophilic population from 1992 to 2001. Intracranial bleeding was the cause of death in 5% of hemophilia A and B patients with all disease severities [7] . Between 1977 and 1999, 11% of the deceased non-severe hemophilia A and B patients from the United Kingdom (UK) died from intracranial bleeding [11] . In a Korean cohort from 1991 to 2012, intracranial bleeding was the cause of death in 34% of the deceased hemophilia A patients with all disease severities [3] . We cannot directly compare the percentages in the above-mentioned four studies with our findings, as our analysis was restricted to fatal intracranial bleeding in only non-severe hemophilia A patients. As the cohorts showing both lower and higher death rates attributable to intracranial bleeding include all disease severities as well as hemophilia B patients, they represent different proportions of non-severe hemophilia A patients. Furthermore, the time periods covered and geographic regions differ. This has implications for the distribution of causes of death, as treatment strategies vary between times and places.
Two previous studies reported SMRs specifically for (intracranial) bleeding [11, 24] . Walker et al. calculated an SMR of 32 for bleeding in all hemophilia types and severities (95% CI 22-46) between 1980 and 1995 [24] . The SMR for intracranial bleeding in non-severe hemophilic patients in the total UK cohort previously mentioned was 9.29 [11] . The SMR for children aged < 5 years was 263 [11] . We found a lower SMR for the non-severe patients in our cohort, which consists only of hemophilia A patients. The UK cohort reported by Darby et al. covers a different time period than our data (1977-1999 and 1996-2010, respectively). As treatment strategies have improved life-expectancy in non-severe hemophilia A patients over the last decades, it is plausible that this improvement explains our lower observed SMR. Furthermore, the SMRs in the UK cohort are for both hemophilia A and hemophilia B patients. Additionally, differences between the general Dutch male population and the general UK male population used to calculate the SMRs could account for the differences in SMRs.
Risk factors and comorbidities
Unfortunately, we had only (limited) data on hypertension as one of the established general risk factors for intracranial bleeding. We could not identify an increased incidence of hypertension in patients with fatal (intracranial) bleeding as compared with patients with other causes of death. No data were available on the use of NSAIDs. Reported specific risk factors for the development of intracranial bleeding in hemophilic patients are disease severity, inhibitor development, Caucasian ethnicity, infection with HIV, prior intracranial bleeding, head trauma, and older age [13, 18] . We could not identify the presence of most of these risk factors (Table 2; Table S1 ). Only two of the 17 patients with fatal intracranial bleeding in our cohort had moderate hemophilia, which represented the distribution of moderate hemophilia A in our cohort.
Patients with fatal intracranial bleeding seemed to be slightly younger. We found only a minor trend for the association between younger age and fatal intracranial bleeding, probably because of low patient numbers. In our cohort, three patients died at a very young age (0-19 years; Table 3; Table S1 ). This awareness is important, as older age has been identified as a risk factor for the development of intracranial bleeding.
The comorbidities of the patients dying from intracranial bleeding show no clear pattern for identifying patients at risk for intracranial bleeding. This implies that caution is needed for all hemophilia A patients, including those with mild disease severity, young patients, and those without viral infections or inhibitors.
Limitations
Efforts were made to enroll all eligible patients, in order to reduce any underestimation of deceased patients. However, we acknowledge the challenges of retrospective collection of mortality data. We possibly missed undiagnosed neonates who died from fatal intracranial bleeding. Additionally, patients were selected on the basis of treatment with FVIII concentrates. As not all non-severe hemophilia A patients have been treated with FVIII, it is possible that we included patients with a more severe disease phenotype and accompanying comorbidities. This may have led to an overestimation of fatal intracranial bleeding and comorbidities. Interestingly, the patients in our cohort seem to be relatively healthy, as no clear pattern of comorbidities could be observed (Table S1) .
We did not find a difference in the prevalence of hypertension between patients who died from fatal intracranial bleeding and patients with other causes of death. This might be attributable to reporting bias, as hypertension may not have been measured with a standard procedure, but may have been discovered during the workup just before fatal intracranial bleeding occurred.
No autopsy reports were available to further specify the cause of bleeding. Furthermore, we do not, unfortunately, have data on non-fatal intracranial bleeding in our patient population. For this reason, we could not calculate the incidence of intracranial bleeding in our cohort.
We used intracranial bleeding death rates of Dutch males as a standard population to calculate the SMR, as these data were not available for a European population. However, these rates might be different across Europe, owing to, for example, different traffic regulations or treatment options for non-hemophilic males with fatal intracranial bleeding. We considered performing a sensitivity analysis in the Dutch hemophilic population, but we were hampered by small patient numbers.
Clinical significance
We found that patients with mild hemophilia have a considerable risk of fatal intracranial bleeding. As comorbidities of the patients dying from intracranial bleeding show no clear pattern identifying high-risk patients, adequate follow-up and instruction of all non-severe hemophilia A patients is essential. Bleeding-related causes of death should be analyzed more frequently for non-severe hemophilia A patients. These numbers will provide insights into areas of care that can be improved in the coming decade, in which the frequency of virus-related causes of death is expected to be reduced, owing to the availability of safer clotting factor products. Future studies should focus on the identification of patients at risk for fatal intracranial bleeding, as this information might help to specifically prevent mortality in patients with risk factors that we could not identify.
Furthermore, recent developments in the identification of genetic risk factors for intracranial bleeding in the general population have enabled the identification of several genetic variants and risk alleles (or promising candidates) [25] . In association with hemophilia A, these variants may increase the risk of fatal intracranial bleeding. This information might help in the prevention or treatment of intracranial bleeding in the future.
Conclusion
This is the first international cohort study to report specific mortality rates for intracranial bleeding in non-severe hemophilia A patients of all ages in the last three decades. Intracranial bleeding was the cause of death in 12% of the patients who died in this large cohort. Non-severe hemophilia A patients showed a 3.5-fold higher rate of mortality from intracranial bleeding than males in the general population (95% CI 2.0-5.8).
Patients who suffered from fatal intracranial bleeding were relatively young, with mostly mild disease severity without clear comorbidities. This profile of deceased patients, together with the change in treatment strategies over time, shows the importance of reporting causes of death to identify areas of care that can be improved. Risk factors for the development of fatal intracranial bleeding need to be identified to enable the prevention or treatment of intracranial bleeding in the future.
Our results show that non-severe hemophilia A patients have an increased risk of dying from intracranial bleeding, which demonstrates the need for specialized care for these patients. Addendum J. I. Loomans and C. L. de Groot-Eckhardt collected, interpreted, cleaned, checked and analyzed the data, and wrote the manuscript. J. G. van der Bom designed the study, supervised the interpretation and statistical analysis of the data, and reviewed and approved the final version of the manuscript. K. Fijnvandraat designed and supervised the study, wrote the protocol, and wrote and edited the manuscript. The other authors collected the data or supervised data collection, and reviewed and approved the final version of the manuscript.
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